We offer a comprehensive range of active intermediate drug development services. With a range of modern synthesis technologies, experience and expertise, we are able to ensure that projects are delivered on time. Our services guarantee reliable product quality and low production costs.
Provides a comprehensive technology project (TP), including all necessary technical support after technology transfer.
All non-infringing/innovative technology projects (TPs) available for licensing and large-scale development include:
- Complete scalable manufacturing processes and procedures
- Preliminary analysis of impurities
- Complete analysis data and methods of analysis (MOA)
- Production cost assessment
- Samples of key intermediates and final active intermediates
- Business models designed to build long-term partnerships for product development & commercialization
Pharmaceutical development & Technology Transfer
Relez Pharma provides CRO & CDMO services of APIs and intermediates, oral solids (tablets, capsules), sterile liquid products (small volume injections-ampoules, small volume injections-vials, eye drops). Through our growing portfolio of innovative API technologies, we can offer a range of research and development production processes that can be implemented and patented.
Project Collaboration
Relez platform provides R&D project cooperation and commercialization, covering the entire pharma industrial value chain from APIs to finished drugs Relez is open to flexible project cooperation with partners, which include but are not limited to research institutions, pharmaceutical companies, biotechnology companies and commercial companies, etc.
In/Out Licensing
Relez is dedicated to developing and providing innovative, valuable drugs to the general public and assisting our business partners to bring high-quality products to global markets. We are highly interested in collaborative opportunities including product license-in and license-out, co-research/co-development, co-promotion/co-marketing.
Joint Venture
For partners with in-depth cooperation, we establish joint ventures (JV Partnership), share resources, and conduct all-around cooperation in research and development, marketing, fundraising and strategic development.
Strategic Partner
The beauty of our partnership-oriented approach is that it creates a network effect, eventually making all our partners part of one big pharmaceutically inclined family. We believe that this network effect allows us to work as a vertically integrated company, being able to leverage our global connections to take on otherwise inaccessible markets.
